Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.

Ester De LeoMohamed A ElmonemSante Princiero BerlingerioMarine BerquezBeatrice Paola FestaRoberto RasoFrancesco BellomoTobias StarborgManoe Jacoba JanssenZeinab AbbaszadehSara CairoliBianca Maria GoffredoRosalinde MasereeuwOlivier DevuystMartin LoweElena LevtchenkoAlessandro LucianiFrancesco EmmaLaura Rita Rega

Published in: Journal of the American Society of Nephrology : JASN (2020)

Our data show that luteolin improves defective pathways of cystinosis and has a good safety profile, and thus has potential as a treatment for nephropathic cystinosis and other renal lysosomal storage diseases.

Keyphrases

single cell
cell therapy
electronic health record
genome wide
stem cells
risk assessment
gene expression
human health
combination therapy
dna methylation
adverse drug
replacement therapy
climate change